An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Inclusion Criteria:

- adult patients, >/=18 years of age

- chronic hepatitis C

- participation in Roche DAA treatment protocol for CHC infection

- DAA-associated resistant mutations persisting through to last evaluation in donor
protocol , or partial viral response or viral load rebound while on RO5024048
treatment, or sustained virological response >/= 20 weeks after last dose of study
medication in donor study

Exclusion Criteria:

- For patients participating in DAA resistance monitoring: Initiation of treatment
after participation in the donor protocol for which there is evidence of
cross-resistance to donor protocol DAA

- For patients participating in DAA SVR durability: Treatment with any anti-HVC therapy
since establishing SVR in the donor study